Stryker Corporation (SYK) has a MoatMap StockRank of 70/100 based on Quality (69/100), Value (32/100), and Momentum (53/100) factor scores. The current signal is BUY. Stryker is a high-quality medical technology compounder with strong switching costs and high ROIC. However, it lacks a direct macro inflection tailwind from our 18-month themes, and its current valuation fully reflects its quality, offering limited asymmetric upside.
Stryker Corporation is a global medical technology leader offering a diverse portfolio of orthopedic implants, medical and surgical equipment, and neurotechnology and spine products used in hospitals worldwide. The company maintains its robust market position through continuous innovation, strong relationships with medical professionals, and a broad product offering that caters to various surgical specialties, creating significant switching costs for healthcare providers.
| Price | $314.01 |
| Market Cap | $117.9B |
| P/E (TTM) | 34.86 |
| P/E (Forward) | 18.02 |
| Price/Book | 5.14 |
| Return on Equity | 15.2% |
| Return on Invested Capital | 12.8% |
| Debt/Equity | 66.30 |
| Gross Margin | 64.7% |
| Operating Margin | 17.8% |
| Revenue Growth | 2.6% |
| Dividend Yield | 1.2% |
| Free Cash Flow | $4.4B |
Stryker Corporation operates in the Medical Devices industry, part of the Healthcare sector (United States).